Results 181 to 190 of about 120,029 (315)
Impact of initial hematocrit levels during direct procurement and perfusion on the likelihood of primary graft dysfunction in donation after circulatory death heart transplantation. [PDF]
Odekunle E +9 more
europepmc +1 more source
Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell +6 more
wiley +1 more source
A mixed-effect model for the evolution of unbalanced longitudinal hematocrit levels in chronic kidney failure patients. [PDF]
Fissuh YH, Nega GB, Hailay A.
europepmc +1 more source
Abstract Background An existing association was noted between leisure time physical activity (LTPA) and quality of life (QOL) after spinal cord injury (SCI). Furthermore, electrical stimulation exercise program has been shown to improve domains of QOL.
Ashraf S. Gorgey +4 more
wiley +1 more source
Hemoglobin suresnes combined with α<sup>0</sup>-thalassemia: Diagnostic challenges and insights from trio-based whole exome sequencing. [PDF]
Liu HL, Huang WT.
europepmc +1 more source
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen +6 more
wiley +1 more source
Beyond Hemoglobin Concentration: How Intravascular Volume Measurements Can Advance Our Understanding of High-Altitude Adaptation. [PDF]
Tremblay JC, Siebenmann C, Stembridge M.
europepmc +1 more source
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley +1 more source

